Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 2 Summary of identified clusters derived from LCA in people with MLTC

From: Multimorbidity clusters and their associations with health-related quality of life in two UK cohorts

Cluster Label

Leading LTCs (within-cluster prevalence [%])

N (%) a

No. of LTCs b, median (IQR)

Female (%)

Most deprived c (%)

Mortality d, n (%)

Predicted probability of cluster membership, mean (SD)

 

18–36 years

 

UKHLS (n = 16,105)

No multimorbidity

 

15,416 (95.7)

0 (0, 0)

54.9

29.6

  

Pulmonary

Asthma (100%), Hypertension (33%), Arthritis (23%), COPD (14%)

270 (1.7)

2 (2, 2)

65.2

30.0

 

0.95 (0.07)

Cardiometabolic

Depression (59%), Hypertension (55%), Diabetes (23%), Arthritis (21%)

251 (1.6)

2 (2, 2)

69.7

35.5

 

0.99 (0.07)

Depression & Asthma

Depression (100%), Asthma (100%)

168 (1.0)

2 (2, 3)

73.8

38.7

 

0.85 (0.13)

 

37–54 years

 
 

UK BIOBANK (n = 194,109)

No multimorbidity

 

151,975 (78.3)

0 (0, 1)

54.6

16.7

2170 (1.4)

 

Hypertension & Diabetes

Hypertension (100%), Diabetes (22%), Painful conditions (22%)

16,126 (8.3)

2 (2, 3)

47.1

25.4

728 (4.5)

0.82 (0.16)

Asthma + 

Asthma (100%), Painful conditions (24%), Psoriasis or eczema (19%)

9680 (5.0)

2 (2,3)

63.8

21.4

247 (2.5)

0.90 (0.16)

Thyroid & Cancer

Thyroid disease (24%), Dyspepsia (24%), Cancer (22%)

6006 (3.1)

2 (2, 2)

70.0

21.3

270 (4.5)

0.99 (0.05

Depression & Anxiety

Depression (100%), Painful conditions (25%), Anxiety (19%)

5250 (2.7)

2 (2, 3)

70.5

27.1

173 (3.3)

0.82 (0.15)

Pain + 

Painful conditions (100%), Dyspepsia (21%), Hypertension (17%)

5072 (2.6)

2 (2, 3)

64.2

22.0

131 (2.6)

0.97 (0.11)

 

UKHLS (n = 16,726)

No multimorbidity

 

14,542 (86.9)

0 (0, 1)

53.4

21.2

  

Pulmonary

Asthma (100%), Depression (36%), Hypertension (35%), COPD (18%)

805 (4.8)

2 (2, 3)

68.7

30.1

 

0.99 (0.03)

Depression, Thyroid & Cancer

Hypertension (62%), Depression (58%), Thyroid disease (25%), Cancer (20%)

485 (2.9)

2 (2, 2)

65.0

25.0

 

0.99 (0.03)

Arthritis + 

Arthritis (100%), Hypertension (50%), Depression (38%)

466 (2.8)

2 (2, 3)

67.2

32.8

 

0.99 (0.04)

Cardiovascular

CHD (100%), Hypertension (57%), Arthritis (38%), Asthma (26%), Diabetes (21%), Stroke (11%)

218 (1.3)

3 (2, 4)

45.0

42.2

 

0.92 (0.11)

Hypertension & Diabetes

Hypertension (100%), Diabetes (100%)

210 (1.3)

2 (2, 3)

51.9

44.8

 

0.81 (0.16)

 

55–73 years

 

UK BIOBANK (n = 308,254)

No multimorbidity

 

185,265 (60.1)

1 (0, 1)

53.3

11.5

9095 (4.9)

 

Cardiometabolic

Hypertension (100%), Painful conditions (33%), Diabetes (28%), CHD (23%), Stroke (8%)

52,740 (17.1)

2 (2, 3)

41.7

18.6

5827 (11.1)

0.81 (0.14)

Pain + 

Painful conditions (51%), Hypertension (34%), Dyspepsia (29%)

33,165 (10.8)

2 (2, 3)

66.0

15.4

2181 (6.6)

0.81 (0.14)

Pulmonary

Asthma (100%), Hypertension (36%), Painful conditions (29%), COPD (12%)

20,624 (6.7)

2 (2, 3)

60.7

15.5

1562 (7.6)

0.68 (0.15)

Cancer + 

Cancer (100%), Hypertension (44%), Painful conditions (27%)

16,460 (5.3)

2 (2, 3)

62.3

13.8

2115 (12.9)

0.79 (0.12)

 

UKHLS (n = 12,308)

No multimorbidity

 

8191 (66.6)

0 (0, 1)

51.5

15.4

  

Hypertension + 

Hypertension (100%), Arthritis (54%), Diabetes (31%)

2162 (17.6)

2 (2, 3)

55.4

22.0

 

0.88 (0.15)

Pulmonary

Asthma (100%), Arthritis (58%), Hypertension (34%), COPD (32%)

730 (5.9)

2 (2, 2)

65.5

20.8

 

0.81 (0.21)

Depression, Thyroid & Cancer

Arthritis (78%), Depression (30%), Thyroid disease (28%), Cancer (27%)

641 (5.2)

3 (2, 4)

68.0

17.6

 

0.94 (0.07)

Cardiovascular

CHD (82%), Hypertension (52%), Arthritis (48%), Diabetes (33%), Stroke (19%)

584 (4.7)

3 (2, 4)

38.7

30.3

 

0.77 (0.16)

 

74 + years

 

UKHLS (n = 4047)

No multimorbidity

 

2161 (53.4)

1 (0, 1)

52.3

15.8

  

Arthritis + 

Arthritis (100%), Hypertension (70%), CHD (31%)

959 (23.7)

3 (2, 3)

66.0

18.4

 

1.00 (0.00)

Cardiometabolic

Hypertension (78%), CHD (49%), Diabetes (40%) Stroke (22%)

547 (13.5)

2 (2, 3)

42.1

19.7

 

1.00 (0.00)

Pulmonary

Asthma (100%), Arthritis (59%), Hypertension (55%), CHD (29%), COPD (24%)

380 (9.4)

3 (2, 4)

61.1

22.4

 

1.00 (0.00)

  1. Clusters identified from LCA in people living with MLTCs. ‘No multimorbidity’ group added for reference. Leading LTCs were defined as the most prevalent 2–3 LTCs within the cluster. Bolded LTCs are over-represented LTCs with higher than expected within and between-cluster prevalence
  2. aN (%) from age group assigned to each cluster (including ‘No multimorbidity’ population added for reference)
  3. bFrom n = 43 LTCs (UK Biobank) or n = 13 LTCs (UKHLS)
  4. c% in cluster from most deprived 20% of UK population based on Townsend scores (UK Biobank [< 0.5% missing data]) or IMD scores (UKHLS [no missing data])
  5. dN (%) from each group that died before start of online follow up in UK Biobank only (defined as 1st January 2019). Mortality data were not available for UKHLS